Rayze Bio
San Diego, US · Founded 2020 · Delaware corporation · 283 employees on LinkedIn · 8 known investors
RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
Founders & leadership
Rayze Bio was founded in 2020 by Ken Song.
KS
Ken SongFounder
BH
Ben HickeyPresident
AB
Abhi Bhat, PhDSenior Vice President, Research & Development
DC
Deborah CharychNamed on SEC filing
YL
Yi LarsonNamed on SEC filing
Board
AR
JD
BK
Bong KohBoard director
AK
Investors · 8
Samsara BioCapitalPalo Alto
Scion Life SciencesNew York · $1K – $60M
Sofinnova VenturesMenlo Park · $100K – $15M
TCG CrossoverPalo Alto
venBio PartnersSan Franciscovia Aaron Royston · board
Versant VenturesSan Francisco · $250K – $5M
Vivo CapitalPalo Alto · $10M – $50M
venBio Global StrategicreportedSan Francisco
Reported raises · per SEC filings
Form D private placements$396.4M disclosed across 4 rounds · 2020–2022
▶$167.9MraisedSep 2022 · 18 investors · BiotechnologyRule 506(b)
▶$167.9MraisedSep 2022 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron KantoffDirector
- Angie YouDirector
- Aaron RoystonDirector
- Yi LarsonDirector
- Aubrey HaddachExecutive Officer
- Mary TagliaferriDirector
- Jerel DavisDirector
- Ken SongExecutive Officer, Director
- Arvind KushExecutive Officer
- Maha KatabiDirector
- Alex RosenDirector
- Offering amount
- $167.9M
- Amount sold
- $167.9M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$108.5MraisedJun 2021 · 23 investors · BiotechnologyRule 506(b)
▶$108.5MraisedJun 2021 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Deborah CharychExecutive Officer
- Aaron RoystonDirector
- Jerel DavisDirector
- Ken SongExecutive Officer, Director
- Bong KohDirector
- Aaron KantoffDirector
- Yi LarsonDirector
- Offering amount
- $108.5M
- Amount sold
- $108.5M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$105MraisedDec 2020 · 17 investors · BiotechnologyRule 506(b)
▶$105MraisedDec 2020 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bong KohDirector
- Ken SongExecutive Officer, Director
- Aaron KantoffDirector
- Jerel DavisDirector
- Aaron RoystonDirector
- Offering amount
- $105M
- Amount sold
- $105M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedNov 2020 · 9 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron RoystonDirector
- Jerel DavisDirector
- Aaron KantoffDirector
- Ken SongExecutive Officer, Director
- Offering amount
- $45M
- Amount sold
- $15M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Rayze Bio went on to found or lead other companies.
Competitors · 1
by search overlapCompanies competing with Rayze Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Rayze Bio do?
- RayzeBio develops radiopharmaceutical therapies for cancer treatment. The company is a subsidiary of Bristol Myers Squibb focused on advancing targeted cancer therapies to patients.
- Who founded Rayze Bio?
- Rayze Bio was founded by Ken Song in 2020.
- Who are Rayze Bio's investors?
- Rayze Bio's investors include Samsara BioCapital, Scion Life Sciences, Sofinnova Ventures, TCG Crossover, venBio Partners, Versant Ventures, Vivo Capital, venBio Global Strategic.
- How much funding has Rayze Bio raised?
- Rayze Bio has disclosed $396.4M raised across 4 rounds.
- Where is Rayze Bio headquartered?
- Rayze Bio is headquartered in San Diego, US.